Launched in 2020, Anifera focuses on developing new compounds for use in combination with antibiotics in disease states across animal health where antibiotics are the first line of treatment.

Anifera’s technology consists of a family of small molecules which, acting through a novel mechanism of action, have been shown to increase the susceptibility of resistant strains of bacteria to antibiotics. With an initial focus on bovine mastitis, significant benefits are expected if the compounds produce a superior bacterial cure more quickly than existing commercial intramammary products.

The company was formed by Stonehaven Incubate and Agile Sciences.